Pharmacy and Therapeutics Committee Agenda for February 2, 2006
The Pharmacy & Therapeutics Committee will meet Thursday, February 2, 2006, from 10:30 a.m. to 3:00 p.m., in Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.
Agenda Items:
1. Proposal: Identification of preferred drugs in the category of Angiotensin Converting Enzyme (ACE) Receptor Inhibitors.
Description: The Committee will review the following drug categories to determine preferred and non-preferred drugs in each therapeutic class:
a. Therapeutic Class: ACE Receptor Inhibitors
Drugs Affected: Accupril (quinapril HCL), Aceon (perindopril erbumine), Altace (ramipril), benazepril HCL, Capoten (captopril), captopril, enalapril maleate, fosinopril sodium, lisinopril, Lotensin (benazepril HCL), Mavik (trandolapril), moexipril HCL, Monopril (fosinopril sodium), Prinivil (lisinopril), quinapril HCL, Univasc (moexipril HCL), Vasotec (enalapril maleate), Zestril (lisinopril).
b. Therapeutic Class: ACE Receptor Inhibitor/Diuretic Combinations
Drugs Affected: Accuretic (quinapril/hctz), benazepril HCL/hctz, Capozide (captopril/hctz), captopril/hctz, enalapril maleate/hctz, fosinopril/hctz, lisinopril/hctz, Lotensin HCT (benazepril HCL/hctz), Monopril HCT (fosinopril/hctz), Prinzide (lisinopril/hctz), Quinaretic (quinapril/hctz), Uniretic (moexipril/hctz), Vaseretic (enalapril maleate/hctz), Zestoretic (lisinopril/hctz).
2. Proposal: Identification of preferred drugs in the category of Angiotensin Receptor Blockers (ARBs).
Description: The Committee will review the following drug categories to determine preferred and non-preferred drugs in each therapeutic class:
a. Therapeutic Class: Angiotensin Receptor Blockers
Drugs Affected: Atacand (candesartan cilexetil), Avapro (irbesartan), Benicar (olmesartan medoxomil), Cozaar (losartan potassium), Diovan (valsartan), Micardis (telmisartan), Teveten (eprosartan mesylate).
b. Therapeutic Class: Angiotensin Receptor Blocker/Diuretic Combinations
Drugs Affected: Atacand HCT (candesartan cilexetil/hctz), Avalide (irbesartan/hctz), Benicar HCT (olmesartan medoxomil/hctz), Diovan HCT (valsartan/hctz), Hyzaar (losartan/hctz), Micardis HCT (telmisartan/hctz), Teveten HCT (eprosartan/hctz).
3. Proposal: Prior authorization of Revatio.
Description: The Committee will consider a proposal to allow Medicaid reimbursement, with prior authorization, for Revatio. The product is not currently available due to the potential for significant misuse. In order to assure access to the drug for approved indications, and avoid misuse and overuse, the DOH is recommending the drug be included in the Clinical Drug Review Program, and dispensed only following completion of a prior authorization process.
a.Therapeutic Class: Pulmonary Hypertension, Select C-GMP Phosphodiesterase T5 Inhibitors
Drugs Affected: Revatio
| 10:30 AM | 10:40 AM | Welcome and Introductions |
| 10:40 AM | 11:40 AM | Comments from Interested Parties* |
| 11:40 AM | 12:15 PM | Clinical Review of ACE Inhibitor Categories |
| 12:15 PM | 12:45 PM | Clinical Review of ARBS Categories |
| 1:00 PM | 1:45 PM | Executive Session / Lunch (evaluation of trade secret supplemental rebate information) |
| 1:45 PM | 2:15 PM | Final Recommendations for Preferred Drugs |
| 2:15 PM | 2:45 PM | Discussion and Recommendations Regarding Revatio |
| 2:45 PM | 3:00 PM | Final Comments and Adjournment |
*Speakers must notify DOH at least 72 hours in advance of their intent to speak at the committee meeting. To get on the agenda, you may call 518-486-3209 or e-mail ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes) and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit a clinical study or clinical report, rather than comments, must submit the study at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.
